Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(IMO) it will be ddssf.pk on yahoo and we in USA can trade it without going the .TO routing .
Any idea, what will happen to current holding of this stock? Can we trade on Toronto stock exchange? How to check daily stock price after 30th june11?
WOW delisting,pinkyland next.What a POS
Waiting for $0.20 to add more in my basket.
Still a ways to go, but good action today!
DDSS Video Chart 4/29/11
www.video.qualitystocks.net
Labopharm Inc. is not a current client of QualityStocks
The drop lately is lack of buying pressure, seems nobody wants to take a chance now and want to wait for some good news. Also some people fear that they won't remain on Nasdaq for much longer. These are all good reasons not to buy in but the pps will be much higher when it feels more safe to invest in ddss. I have a lot of confidence in the potential of this company.
I saw from YMB that reimbursement for Oleptro is already in...well, at least the thread was alluding to that. I'm not in DDSS. I was at some point and just looking back why the drop. Will continue to monitor....
No news yet , but yes I am tired of talking to myself lol. I'll wait until we have more action before I talk some more over here. the company is still young and relatively unknown. Once Tramacet twice daily comes out we'll be laughing, that product has potential!!
done talking to yourself yet? btw, did you hear about the reimbursement on medicare? do you have news on this? TIA
Might buy more before we get a nice jump up, just hope we also have good news to go with it so we can stay above 1 dollar after the pps goes up.
It's always scary to buy at these times, but it's never comfortable to buy right before a breakout in pps, ddss has done that time and time again in the past, it would be nice to see that again!!!
Very risky, but what a great time to buy if you have some money you can afford to lose. I've decided to add to my position in the morning if it stays flat. I wouldn't be surprise if this went up 5 fold in the near future. Again, it is risky because the company is still struggling, but sales may have improved and their next product coming out I know has a lot of potential!!!! I'm not gonna let this one slip, putting some money into it. I think it will likely surprise a lot of people it has time and time again in the past, just when you think it's heading to zero it shoots right up.
The fact that it's not going any lower after the last pr makes me think that the people that have shares aren't ready to sell anytime soon and the potential buyers are just waiting for some news to spark things, hang in there, patience will potentially help you win big here.
I agree they want to stay listed,the pumping will start soon (IMO)
I don't think they'll let themselves get off of Nasdaq. They've worked too hard and have too much potential to let it slip, they'll find a way to make sure the pps is above 1 dollar by June and I think it'll be up quite a bit higher than that. Risky stock, but one that some people might make a lot of money in.
Can't wait for this to take everyone by surprise and go back to 3 dollars pretty quick!!!
The RSI at 24,any number below 30 is know as oversold.
What do you mean obver sold?
Very thin wall between 0.62 and 0.70. Just need a little something to get it going.
I love the fact that it didn't go much lower and very low volume. It may not shoot up in the next week or so but I do believe our time will come soon enough and it will be an increase in pps higher than anyone had ever imagined. Have a great weekend everyone!
Be nice to see some news come out in the short term; Long Term I agree should be interesting.
They might figure it out and get sales going but the once daily trazadone will be a challenge because there is so much competition and trazadone is likely not better. It's the next product I'm super excited about, so much potential. For the record I never believed once a day trazadone was worth spending money on.
The problem as I see it is the sales of the new drug are lower than estimated,time to fire some deadbeat sales people and get some pros selling the product.The product is good but sales suck (IMO)
When it gets to 5 bucks in a short period of time you'll have people saying, why didn't I buy when it was so low? That's a good question, but right now everybody is scared because it seems it will keep going down forever. I sometimes wonder if I'm the only one that's seeing this. Good luck everyone!!
FYI: 5 dollars will only be the beginning.
Mark my words, this stock and company will take millions of people by surprise. As a pharmacist I believe their next product in the pipeline has more blockbuster potential than any other product out there. Until stem cells hit it big, this company is the next big drug company. Mark my words!
Sounds like a plan!
The reason for this kind of drop is amateurs selling at market price instead of being somewhat patient and putting a limit, if you're in that much rush to sell this stock you definitely weren't in it for the right reasons, probably playing with money you need to put food on the table.
This is all panic selling, people that should have never been in the stock to begin with. This is a speculative buy, if you believe in the company you buy this stock and stay patient, realizing you could lose a big chunk or multiply your money by 10 if we get great news. The market cap is tiny, so much room to go much higher.
Volume dry up this afternoon, i don't think too many people are willing to sell any lower. This could fly soon even without news, to at least 1 dollar
Scary to buy here, but that's where you make big money, buying when nobody else wants to. I had promised myself I would buy a lot if it went down to 70cents and here I was for several hours convincing myself not to buy here. It may go down a little more from here, but if it does start going up again I believe we can go pretty high and make some huge gains. Their next product has a lot more potential than once a day trazadone, that product does have much potential it doesn't matter how much they try to sell it.
Couldn't agree with you more!
DDSS back on the watch radar for a possible bottom once the overall markets settle down....
Well, I think the market has proven you wrong.
Well so much for there sales staffs ability to sell the product,new lows-thanks sales staff.
I hope its better than the last one. Good luck.
Looking forward to next week and seeing the sale numbers,
"conference call on Thursday, February 24, 2011 at 8:30 a.m. (ET) to discuss its fourth quarter 2010 progress and financial results. Labopharm will report its fourth quarter 2010 financial results via news release before the markets open the same day"
I wish you the best
Smitter SMTT
I just put my life savings in DDSS.
Let's see if .80 holds or not
Smitter SMTT
I agree, great buying opp
Smitter SMTT
Wow this one is so undervalued and the beauty is that I think the market will realize that soon. They have revenues already unlike a lot of small drug companies and they have some in the pipeline that aren't far from approval with huge potential. Holding on to this one for the long haul!!!
Expecting some nice gains from here now that the Cdn. approval of Oleptro is confirmed.
Nice NEWS!!!!!!!!!!!!
Labopharm Receives Health Canada Approval for Oleptro(TM): a New Once-Daily Antidepressant for the Treatment of Major Depressive Disorder
Share
retweet
EmailPrint..Companies:Labopharm Inc.Labopharm Inc..Related Quotes
Symbol Price Change
DDS.TO 0.96 +0.07
{"s" : "dds.to,ddss","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Labopharm Inc. On Thursday January 20, 2011, 9:46 am EST
- Company Advancing Partnership Discussions and Preparing for Canadian Launch -
LAVAL, QC, Jan. 20 /PRNewswire/ - Labopharm Inc. (TSX:DDS.to - News) today announced that Health Canada's Therapeutic Products Directorate (TPD) has approved OLEPTRO(TM) (trazodone hydrochloride Extended Release Tablets), a novel once-daily formulation of the antidepressant trazodone, for the symptomatic relief of Major Depressive Disorder (MDD) in adults. OLEPTRO(TM) acts as a serotonin antagonist reuptake inhibitor (SARI), providing physicians and patients in Canada with a new option in the treatment of MDD.
"We are pleased to announce the approval of OLEPTRO(TM) in Canada - the second approval for this drug in 12 months," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Our plan is to commercialize OLEPTRO(TM) in Canada with a marketing partner and we are advancing discussions towards this end, while at the same time preparing for the launch of our product."
MDD is a common mental illness often characterized by a combination of emotional, somatic and behavioral symptoms.(1) Approximately 1.6 million Canadians suffer from depression in a given year and more than one in ten Canadians over the age of 15 will suffer from depression during their lifetime. The incidence is highest among women and in younger age groups, and the strongest risk factor is having a family history of major depression. Depression is one of the leading causes of disability globally. Sales of antidepressants in Canada in 2009 totalled almost $1 billion.
Nearly 28 percent of patients being treated with antidepressants stop taking their medication within the first four weeks of treatment and as many as 44 percent stop within the first 12 weeks, due to reasons such as lack of efficacy, exacerbation of symptoms, including sleep disturbance and agitation, and/or adverse events such as weight gain or sexual dysfunction.(2)
"OLEPTRO(TM) offers Canadian physicians a therapeutic alternative for treating their patients with major depressive disorder, one that combines the mechanism of action of a serotonin antagonist reuptake inhibitor, or SARI, with a novel once-daily dosing option," said Dr. Jeffrey Dayno, Chief Medical Officer, Labopharm Inc. "This is important because we know that patients with MDD present with unique symptom profiles and respond differently to treatment. Physicians appreciate options to better individualize patient care."
OLEPTRO(TM) utilizes CONTRAMID(R), Labopharm's clinically validated technology that controls the release of active substances within oral medications
Labopharm (DDSS) - Significantly undervalued stock
Tridural - No. 1 Selling in Canada
"Most proud of Tridural, which was licensed from Labopharm. The pain treatment is the No. 1 extended release tramadol drug in Canada, with a 47% market share, compared with a tramadol drug made by Biovail, which has a 30% share", CEO Jonathan Goodman (Paladin Labs), says in an exclusive interview with BioTuesday.ca.
OLEPTRO™ Launched in the U.S. Market
OLEPTRO™, a novel once-daily formulation of the antidepressant trazodone, was launched in the U.S. by Angelini Labopharm, Labopharm's joint venture with Gruppo Angelini. "We are encouraged by the positive early trends in feedback and use of OLEPTRO™ since launch and continue to believe that OLEPTRO™ is a valued option in the treatment of depression." said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc
Canadian Regulatory Decision on Once-Daily Antidepressant Anticipated
Labopharm anticipates a decision on its New Drug Submission (NDS) for once-daily trazodone to be rendered everyday now by Health Canada.
Twice-Daily Tramadol/Acetaminophen Product Approved in Europe
Labopharm's twice-daily tramadol/acetaminophen received a positive opinion under the European Union Decentralized Procedure (DCP) in eight countries (Czech Republic, Iceland, Ireland, Poland, Portugal, Slovakia, Slovenia and Spain). Marketing Authorization (MA) will be granted in each country subject to the approval of translations of the Summary of Product Characteristics (SPC) and other labeling documents. Labopharm is working with its marketing partner, Grünenthal GmbH, towards launching the product in multiple European markets late next year.
Established Marketing Partnership for Twice-Daily Tramadol/Acetaminophen Product in Africa
Subsequent to the end of the third quarter, Labopharm established an exclusive distribution and supply agreement for its twice-daily tramadol/acetaminophen with Paladin Labs Inc. for 13 countries in Sub-Saharan Africa, including South Africa.
Commercialization of Differentiated Products Using Three Technology Platforms
"As we move forward, we continue to focus on the development and commercialization of differentiated products using our three technology platforms - our proven CONTRAMID(R) platform, our promising abuse- and misuse-deterrent platform, INTELLITAB(TM), and our PNDS(TM) platform for the optimized delivery of water-insoluble drugs and, potentially, short interfering ribonucleic acid (siRNA), a rapidly emerging area of drug delivery." said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc.
Established First Marketing Partnerships for INTELLITAB™-Based Product
Also subsequent to the end of the third quarter, Labopharm established exclusive distribution and supply agreements for Canada and 13 Sub-Saharan African countries, including South Africa, with Paladin Labs Inc. for its misuse deterrent and tamper resistant INTELLITAB™ formulation of oxycodone/acetaminophen. The agreements are the first marketing partnerships for Labopharm's INTELLITAB™ technology platform.
Labopharm Monetizes Royalty Stream From Purdue for Ryzolt(TM)
"The monetization of the future expected royalty payments from RYZOLT(TM) provides Labopharm with additional liquidity as we commercialize new products such as OLEPTRO(TM) and twice-daily tramadol-acetaminophen," said James R. Howard-Tripp, President and Chief Executive Officer of Labopharm Inc.
Share Price : 0.93$
DDSS Is the best choice for short and long term on these levels without a doubt.
Look also for Investor Presentation January 2011:
http://www.labopharm.com/docs/Investor%2...
Good Luck!
I would like to welcome Mdeskm to the DDSS board, as our newest Assn't mod
Smitter SMTT
I will do some DD over the weekend
Smitter SMTT
Chart seems to be bottoming out
Smitter SMTT
Followers
|
24
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1202
|
Created
|
06/01/07
|
Type
|
Free
|
Moderators |
Board of Directors
Santo J. Costa 3
Mark D'Souza
Julia Brown 1
Richard J. MacKay 3
Frédéric Porte 2
Jacques Roy 1,2
Rachel R. Selisker 1,2
Officers
Mark D'Souza
President and CEO
Damon Smith
Senior Vice-President, Research and Development
Gregory M.C. Orleski
Vice-President, Business Development
Jeffrey M. Dayno, M.D.
Chief Medical Officer
Sylvain Guénette, CA
Chief Financial Officer
Sybil Skinner-Robertson
Vice-president, Regulatory Affairs
Labopharm, Inc.
(Head Office)
480 Armand-Frappier Blvd.
Laval, Quebec, H7V 4B4
Canada
Tel: (450) 686-0207
Fax: (450) 686-9141
Labopharm USA, Inc.
202 Carnegie Center,
Suite 204
Princeton, NJ 08540
United States
Tel: (609) 454-0207
Fax: (609) 454-0202
Labopharm Europe Limited
5, The Seapoint Building
44 Clontarf Road
Dublin 3, Ireland
Tel:+353 (0)1 854 0140
Fax:+353 (0)1 854 0144
Labopharm, Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers a once-daily formulation of the pain-killer, tramadol to treat patients with moderate to severe pain in the United States, Europe, Mexico, Latin America, and the Caribbean. The company conducts Phase III clinical studies for once-daily formulations of Trazodone, an antidepressant; Phase I clinical studies for Tramadol combination products to meter the dispersion of two active ingredients for clinically beneficial interaction between the drugs;
Phase I clinical studies for abuse resistant formulations of an opioid drug to provide patient safety; and Phase I clinical studies for anti-inflammatory products. It also develops a once-daily formulation of betahistine, an oral histamine analogue, for the treatment of the symptoms related to Meniere's disease, a disorder characterized by recurrent vertigo and hearing loss; and DDS-2001, an undisclosed formulation in Phase I studies. Labopharm's products are based on Contramid platform, a drug delivery technology that meters the release of drugs from orally administered solid dosage forms, such as tablets. In addition, it develops polymeric nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs, as well as for developing intravenous and oral formulation product candidates. The company was founded in 1990. It was formerly known as Centre de recherche appliquee pharmaceutique CRAP, inc. and changed its name to Labopharm, Inc. in 1994. Labopharm, Inc. is headquartered in Laval, Canada.
overview
http://finance.yahoo.com/q/ks?s=DDSSF.PK+Key+Statistics
Shares Outstanding5: 71.57M
Float: 71.11M
6-K | Jul 12, 2011 | Jul 12, 2011 | 10.6 KB | PDF RTF HTML |
15-12G | Jul 12, 2011 | 10.3 KB | PDF RTF HTML XLS |
FORM 6-K
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8038056
http://rttnews.com/ArticleView.aspx?Id=1184469&pageNum=2978_5599_8156_8314_1
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |